Iradimed Corp

Research Iradimed Corp (IRMD) on Bullrun: valuation model: 4.1% overvalued, market cap USD 1.20B, P/E 51.2, dividend yield 1.3%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIRMD
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryMedical Devices
• CurrencyUSD
• Valuation signal4.1% overvalued
• Market capUSD 1.20B
• P/E51.2
• Dividend yield1.3%
• Financial periodFY2025
• RevenueUSD 83.81M
• Revenue growth14.4%
• Net incomeUSD 22.48M
• Free cash flowUSD 17.18M
• Gross margin76.7%

Valuation Snapshot

Bullrun's latest valuation model marks Iradimed Corp as 4.1% overvalued; latest market cap is USD 1.20B; P/E is 51.2; dividend yield is 1.3%.

About Iradimed Corp

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.

Frequently asked questions

Is Iradimed Corp overvalued or undervalued?

Bullrun's valuation model currently marks Iradimed Corp as 4.1% overvalued.

What is Iradimed Corp's market cap?

Iradimed Corp's market capitalization is USD 1.20B.

What is Iradimed Corp's P/E ratio?

Iradimed Corp's price-to-earnings (P/E) ratio is 51.2.

Does Iradimed Corp pay a dividend?

Iradimed Corp has a dividend yield of 1.3%.

What does Iradimed Corp do?

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories.